Blood plasma derivatives are products produced from plasma by chromatographic and other fractionation techniques. These are used to treat rare disease such as hereditary angioedema, also known as genetic chronic obstructive pulmonary disease (CODP), alpha-1 antitrypsin deficiency, congenital fibrinogen deficiency and Kawasaki disease (KD).
CSL Behring, and Grifols, SA – are Notable Market Players in the Global Blood Plasma Derivatives Market
Leading companies operating in the global blood plasma derivatives market has undertaken various organic and inorganic growth strategies. The global blood plasma derivatives market comprises Grifols, S.A., SK Plasma Co., Ltd., Fusion Healthcare, Green Cross Corp, Kedrion, LFB S.A., Octapharma AG, CSL Limited, and Takeda Phamraceutical Company Limited. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as product launches in the global blood plasma derivatives market, resulting in the market’s growth. Moreover, the market players have also deployed several inorganic strategies, including mergers & acquisitions and collaborations that helped the Company to strengthen its revenue, which allows the Company to hold a strong position in the market.
Below are the major growth strategies undertaken by the players operating in the global blood plasma derivatives market:
|
YEAR |
NEWS |
|
Apr-2022 |
Grifols announced the completion of the acquisition of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, a German company that holds 89.88% of the ordinary shares and 1.08% of the preferred shares of Biotest AG. Following the completion of the Public Takeover Offer (PTO) and the closing of the acquisition of Tiancheng (Germany) Pharmaceutical Holdings AG, Grifols controls 96.20% of the voting rights and holds 69.72% of the share capital of Biotest AG. |
|
Feb-2022 |
Grifols announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis. As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of AT-III, a plasma protein that treats patients with blood clotting issues. |
|
Jan-2022 |
Kedrion and LFB joined forces in an industrial cooperation agreement to increase the availability of Immunoglobulin, a plasma-derived medicine, for patients in France. According to the agreement, Kedrion will manufacture Immunoglobulins in Hungary from LFB plasma collected in France by the Etablissement Français du Sang. These Immunoglobulins manufactured by Kedrion will be imported by LFB in France and will complement LFB’s own Immunoglobulins, which will be made available to hospitals throughout the country, in agreement with and under the control of French health authorities. |
|
July-2022 |
Takeda announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. Data show that HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] reduced relapse rate versus placebo in CIDPpatients when used as a maintenance therapy. |
|
Jun-2021 |
Kedrion Biopharma and Kamada Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved a label update for KEDRAB (Rabies Immune Globulin [Human]), establishing the product’s safety and effectiveness in children. |
